On November 6, 2024 QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, reported that Phase Ⅱ Clinical Data of its Q-1802 program will be presented at SITC (Free SITC Whitepaper) 39th annual meeting hold at Houston on November 8–9, 2024 (Press release, QureBio, NOV 6, 2024, View Source [SID1234647864]). The abstract will be found in 39th SITC (Free SITC Whitepaper) annual meeting abstract (#1500), meanwhile the poster will be presented on November 9 at George R. Brown Convention Center level 1 exhibit Halls AB, Houston. A brief of the abstract information is shown as below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A phase II trial of bispecific antibody Q-1802 in patients with relapsed or refractory solid tumors
Authors: Yakun Wang, Jifang Gong, Xiangdong Qu, Lin Shen
Q-1802 can target both the tumor-specific antigen Claudin18 isoform 2 (CLDN18.2) and the immune checkpoint PD-L1.
The objective response rate (ORR) is approximately 70.0% (14/20) in the 10 mg/kg group.
The proportion of Grade 3 and above adverse events in the 10 mg/kg group is approximately 55%, with good safety profile. There is no adverse events above Grade 3 and Q-1802 related death.
Clinical Data shows that Q-1802 has significant anti-tumor activity.
About Q-1802
Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific antibody. It recruits multiple immune mechanisms to kill tumor cells, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 exhibits high affinity and selectivity, and patients with low or high expression of CLDN18.2 can benefit from it. The molecular design of Q-1802 is rational and effective, the production process is robust with high yield.
Also in this conference, QureBio revealed its T-cell engage and T cell engager enhancer platforms, which can be used to develop bispecific antibodies to treat cancer and autoimmune diseases.